Whalesbook
Fidelity Boosts Pharma Stake Amid Sector Optimism
Fidelity Securities Fund, through its Fidelity Blue Chip Growth Fund, invested ₹308.7 crore in Onesource Specialty Pharma, acquiring a 1.76% stake. This strategic move occurred as Authum Investment & Infrastructure and Nova Global Opportunities Fund offloaded shares valued at ₹118.9 crore and ₹161.85 crore, respectively. Onesource's stock responded with a 0.7% uptick to ₹1,560.70 on high volumes. The Indian pharmaceutical sector, particularly contract development and manufacturing organizations (CDMOs), is projected for strong growth in 2026. Analysts maintain a positive outlook with a consensus 'Buy' rating and an average 12-month target price of ₹1,943.50, suggesting a potential upside of over 26%. Despite a high trailing P/E ratio of approximately 101.10, the company's strong EBITDA margins and expansion plans position it to capitalize on upcoming opportunities. However, modest stock performance over the past year suggests recent institutional interest may be a forward-looking catalyst, though execution risks and the already optimistic valuation warrant attention.
Ownership Shifts in Jewelry, Telecom Sees Speculative Surge
In the jewelry sector, Thakkar Vardhilal Shivrambhai exited Shringar House of Mangalsutra entirely, divesting 15.55 lakh shares for ₹31.9 crore. Wiinance Financial Services and Arthkumbh Ventures LLP emerged as buyers. Shringar's stock saw a modest 1.76% increase to ₹205.36. While one analyst suggests a 'Strong Buy' with a price target of ₹315, MarketsMojo rates the stock a 'Hold' due to technical signals, despite solid fundamentals. The broader Indian jewelry market, while facing elevated gold prices, has shown resilience.
Meanwhile, Shyam Telecom experienced a sharp 20% upper circuit, closing at ₹12.84, following Meghna Agarwal's acquisition of a 0.97% stake for ₹14.01 lakh. This surge is in stark contrast to the company's financial standing. Shyam Telecom exhibits a negative P/E ratio (around -2.08), negative book value, and declining earnings. Its market capitalization hovers around ₹11-14 crore, and its stock has declined significantly over the past year. The current rally appears driven by speculative interest rather than fundamental strength, making it a high-risk proposition.
Mixed Outlooks for Companies
For Onesource Specialty Pharma, analysts project a median target price of ₹1,943.50, indicating confidence in its growth, but investors should consider potential execution challenges and regulatory hurdles. Shringar House of Mangalsutra faces a more balanced outlook, with a 'Hold' rating and a target price of ₹315 suggesting stability rather than aggressive growth, especially given the uncertainty from the promoter's exit. Shyam Telecom's future remains highly uncertain due to its distressed financial condition, making any upward movement without fundamental improvement unsustainable and purely speculative.